These changes suggest that downstream Parkin accumulation follows upstream PINK1 deficiency, and rapamycin promotes mitophagy and remains its protective effects under ApoE4 condition, and it is likely to gain more attention as an AD therapeutical target. The gene discussed is APOE; the disease is Alzheimer disease.